Search
Belzutifan
go.drugbank.com/drugs/DB15463ApprovedInvestigationalBelzutifan is an inhibitor of hypoxia-inducible factor 2α (HIF-2α) used in the treatment of von Hippel-Lindau (VHL) disease-associated cancers. The HIF-2α protein was first identified in the 1990s by researchers at UT Southwestern Medica...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesSparsentan
go.drugbank.com/drugs/DB12548ApprovedInvestigationalSparsentan is a dual antagonist of the endothelin type A receptor (ETAR) and the angiotensin II (Ang II) type 1 receptor (AT1R) with a similar affinity for both (9.3 nM for ETAR and 0.8 nM for AT1R). Sparsentan is first in its class and ...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesPF-06282999
go.drugbank.com/drugs/DB11683InvestigationalPf 06282999 is under investigation in clinical trial NCT01626976 (A Study To Assess The Safety, Tolerability And Pharmacokinetics Of PF-06282999 Administered Orally In Healthy Adult Subjects).
Dabigatran etexilate
go.drugbank.com/drugs/DB06695ApprovedInvestigationalDabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor dabigatran. Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom ...
Categories: P-glycoprotein substratesRabeprazole
go.drugbank.com/drugs/DB01129ApprovedInvestigationalRabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersGallium Ga-68 gozetotide
go.drugbank.com/drugs/DB16019ApprovedInvestigationalGallium (Ga) 68 prostate-specific membrane antigen (PSMA)-11, or Ga-68 gozetotide, is a radiopharmaceutical agent used to identify and assess prostate-specific membrane antigen (PSMA)-positive lesions in adult men with prostate cancer du...
PF-06260414
go.drugbank.com/drugs/DB15221InvestigationalPF-06260414 is under investigation in clinical trial NCT02070939 (Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects
PF-232798
go.drugbank.com/drugs/DB14813InvestigationalPF-232798 is under investigation in clinical trial NCT01140425 (Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects).
Synonyms: PF-00232798Avacopan
go.drugbank.com/drugs/DB15011ApprovedInvestigational[A240249, A240254] Despite complex pathophysiology, studies over the past ~2 decades have identified a key role for the alternative complement pathway and, in particular, the interaction between the anaphylatoxin
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPF-06751979
go.drugbank.com/drugs/DB15105InvestigationalPF-06751979 is under investigation in clinical trial NCT03126721 (The Study is to Evaluate the Effect of Multiple Doses PF-06751979 on the Pharmacokinetics of Midazolam in Healthy Adults).